HIT Consultant September 15, 2021
Tiffany Siu Woodworth, Director, Analytic Solutions, Panalgo

In 2016, the 21st Century Cures Act was signed into law, mandating that the FDA “establish a program to evaluate the use of real-world evidence (RWE) to help support the approval of new indications for a drug and to help to support or satisfy post-approval study requirements.” Along with advances in the availability and quality of real-world data (RWD) from sources like electronic health records (EHRs), registries, medical claims and pharmacy data, the Cures Act has been a catalyst for increased emphasis on using RWE in clinical and regulatory decision-making.  

Today, RWE is playing an increasingly important role in life sciences research. In the last 10 years, close to 1,600 clinical trials have been registered that were informed using RWE....

Today's Sponsors

Patient Bond
pCare
Institute for Healthcare Improvement

Today's Sponsors

Oliver Wyman
Patient Bond

Today's Sponsor

Patient Bond

 
Topics: Biotechnology, Cures Act, FDA, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars
A biotech wins the first FDA drug approval in a rare type of eye cancer
CRISPR: Maximizing this Revolutionary Genetic Tool While Minimizing IP Risk
Concerns Mount Over Limited Evidence for Accelerated Approvals
Pharmacy Education and Practice.